Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
This trial is active, not recruiting.
|Condition||efficacy and safety of ranibizumab (lucentis)|
|Treatment||lucentis intravitreal injections|
|Start date||April 2015|
|End date||January 2017|
|Trial size||21 participants|
|Trial identifier||NCT02140411, CRFB002DCL01|
Lucentis® (ranibizumab) is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion and age-related macular degeneration.
Currently, there is limited epidemiologic information in Chile regarding the incidence of DME and limited experience of anti-VEGF hospital therapy. This study will evaluate the efficacy of intravitreal ranibizumab in Chilean DME patients, to investigate the anatomical and functional improvement following this treatment and to increase the local experience regarding the use of anti-VEGF in the treatment of diabetic macular edema.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Mean Change from baseline in Best Correct Visual Acuity (BCVA)
time frame: 48 weeks
National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) composite score
time frame: 48 weeks
Male or female participants at least 18 years old.
- Diagnosis of macular edema due to diabetes (confirmed by fundus photography, and/or fluorescein angiography, and/or OCT) in at least one eye.
- Vision impairment due to DME (BCVA ETDRS letter score at 4 meters between 20 and 70 letters (6/12 - 3/60 at Snellen chart).
- Blood pressure >160/100 mmHg. 4. Proliferative Diabetic Retinopathy. Any other protocol inclusion/exclusion criteria that may apply.
|Official title||Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.|
Call for more information